rest-of-asia-pacific Vaccines Market Size, Share,Trends, Growth Analysis Report, 2030

Name: rest-of-asia-pacific Vaccines Market Size, Share,Trends, Growth Analysis Report, 2030
Creator: MarketsandMarkets

Overview Request Sample Pages Request Customization Download PDF

You are viewing: Rest Of Asia Pacific Vaccines Market analysis

Part of: Vaccines Market (Global)

The Rest Of Asia Pacific Vaccines Market was valued at $187.8 Million in 2025 and projected to reach to $290.3 Million by 2030, representing a compound annual growth rate of 9.1%. The Rest Of Asia Pacific vaccines market is poised for significant expansion, growing from USD 187.8 million in 2025 to USD 290.3 million by 2030.

Rest Of Asia Pacific Vaccines Market (2025-2030) : Size and Share

CAGR of

USD Million

Rest Of Asia Pacific Vaccines Market Trends and Insights

Rest Of Asia Pacific demonstrates strong growth momentum driven by increasing immunization awareness, expanding healthcare infrastructure, and rising government vaccination initiatives across emerging economies.
The region's vaccines market in Rest Of Asia Pacific benefits from growing population health consciousness and improved access to preventive healthcare solutions. Rest Of Asia Pacific's 9.1% compound annual growth rate significantly outpaces global trends, reflecting the region's accelerating demand for routine and novel vaccines.
Rest Of Asia Pacific is witnessing heightened investment in cold chain logistics and vaccine distribution networks, supporting market penetration in underserved areas.
By 2030, Rest Of Asia Pacific is expected to solidify its position as a high-growth vaccine market, driven by demographic expansion, rising disposable incomes, and strengthened public health frameworks across the region..

Key Market Statistics

CAGR (2025-2030) 9.1% CAGR
Market Size, 2025 ~USD 187.8 Million
Forecast, 2030 ~USD 290.3 Million
Country Rest Of Asia Pacific

Rest Of Asia Pacific Vaccines Market Overview

Strong Regional Growth Trajectory :

Rest Of Asia Pacific vaccines market is expanding at 9.1% CAGR, outpacing the global average of 7.3%, reflecting accelerating immunization adoption across emerging economies in the region.

Expanding Healthcare Infrastructure :

Increasing government investments in healthcare facilities and cold chain logistics across Rest Of Asia Pacific countries are enabling wider vaccine distribution and accessibility in underserved areas.

Rising Immunization Awareness :

Growing public health campaigns and educational initiatives in Rest Of Asia Pacific are driving demand for routine and preventive vaccinations, particularly among pediatric and adult populations.

Government Vaccination Initiatives :

Strengthened national immunization programs and public-private partnerships in Rest Of Asia Pacific are expanding vaccine coverage and supporting market growth through subsidized vaccination schemes.

Rest Of Asia Pacific Vaccines Market Dynamics

This robust 9.1% CAGR reflects increasing healthcare spending, improved vaccine accessibility, and strengthened immunization programs across emerging economies in the region.
Government initiatives and rising disease awareness are key growth catalysts. Looking ahead, Rest Of Asia Pacific will benefit from enhanced healthcare infrastructure development, growing middle-class populations, and increased focus on preventive healthcare.
Rising investments in vaccine manufacturing capabilities and cold chain networks will further support market penetration.
The region's young demographic profile and expanding healthcare budgets position it as a high-growth opportunity for vaccine manufacturers and healthcare providers..

Market Ecosystem

VACCINES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY	USE CASE DESCRIPTION	BENEFITS
	Moderna’s new center at the Harwell science campus, which is home to over 250 organizations in health, technology, and energy, will manufacture mRNA vaccines for the NHS’s seasonal immunization programs \| The facility already has a license to produce COVID-19 vaccines and is preparing to apply for regulatory approval to manufacture flu vaccines as well.	Strengthens domestic mRNA vaccine manufacturing capacity, enhancing the UK’s preparedness against emerging infectious diseases and seasonal threats \| Accelerates the availability of advanced vaccines within the NHS, reducing reliance on international supply chains \| The new facility also encourages further innovation in mRNA vaccine technology and supports rapid scale-up during future public health emergencies.
	After a series of vaccine expansion projects, Sanofi is pursuing a new strategy to extend the reach of its immunizations in Vietnam \| Partnering with the Vietnam Vaccine Company (VNVC), Sanofi has initiated a technology transfer for vaccine production, aiming to eventually manufacture select Sanofi vaccines locally within Vietnam.	Crucial as it expands local manufacturing capabilities, reducing dependence on imports and strengthening supply chain resilience in Southeast Asia \| Access and affordability could significantly improve, helping to address public health needs more efficiently.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Pharmaceuticals

Top Technologies

Top Companies

Key Takeaways

Rest Of Asia Pacific vaccines market valued at USD 187.8 million in 2025, expanding to USD 290.3 million by 2030 at 9.1% CAGR
Rest Of Asia Pacific outpaces global growth rate of 7.3%, driven by emerging economy immunization expansion and healthcare infrastructure investment
Rest Of Asia Pacific benefits from rising government vaccination programs, improved cold chain capabilities, and increasing preventive healthcare adoption
Rest Of Asia Pacific represents a high-growth opportunity for vaccine manufacturers targeting emerging markets with expanding middle-class populations

Vaccines Market Report Scope

Report Metric	Details
Base Year	2025
Fastest Growing Segment	PNEUMOCOCCAL DISEASE (Disease Indication)
Forecast Period	2025–2030
Growth Rate	CAGR of 7.3% from 2025 to 2030
Largest Segment	INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (Route Of Administration)
Market Size Base Year (Billions)	~USD 47.75 (2025)
Revenue Forecast (Billions)	~USD 67.91 (2030)
Segments Covered	Disease Indication, Technology, Type, Route Of Administration, End User

Rest Of Asia Pacific Vaccines Market Report Segmentation

5 segment dimensions are covered across the global market.

By Disease Indication

Combination Vaccines
Covid-19
Dtp
Hepatitis
Herpes Zoster
Hpv
Influenza
Meningococcal Disease
Mmr
Other Disease Indications
Pneumococcal Disease
Polio
Rotavirus
Rsv
Varicella

By Technology

Conjugate Vaccines
Inactivated & Subunit Vaccines
Live Attenuated Vaccines
Mrna Vaccines
Other Covid-19 Vaccines
Other Vaccines
Recombinant Vaccines
Toxoid Vaccines
Viral Vector Vaccines

By Type

Monovalent Vaccines
Multivalent Vaccines

By Route Of Administration

Intramuscular & Subcutaneous Administration
Oral Administration
Other Routes Of Administration

By End User

Adult Vaccines
Pediatric Vaccines

Target Audience

Vaccine Manufacturers & Pharma Companies : Need Rest Of Asia Pacific-specific market data to identify expansion opportunities, assess regional demand for vaccine portfolios, and develop localized commercialization strategies in high-growth emerging markets.
Healthcare & Immunization Organizations : Require detailed Rest Of Asia Pacific market insights to optimize vaccination program planning, allocate resources efficiently, and understand regional immunization coverage gaps and opportunities.
Investment & Private Equity Firms : Seek Rest Of Asia Pacific vaccines market analysis to evaluate investment opportunities in healthcare infrastructure, vaccine distribution networks, and emerging market healthcare companies with growth potential.
Government & Public Health Agencies : Need Rest Of Asia Pacific regional data to inform national immunization policies, budget allocation for vaccination programs, and strategic healthcare infrastructure development initiatives.
Healthcare Consultants & Analysts : Require comprehensive Rest Of Asia Pacific market intelligence to support client advisory services, competitive benchmarking, and strategic recommendations for healthcare and vaccine sector stakeholders.

Key Companies in the Rest Of Asia Pacific Vaccines Market

Company	HQ	Ownership	Strongest segments
ATS AUTOMATION TOOLING SYSTEMS INC	Canada	Public Company	Engineered automated manufacturing and assembly systems,Pre- and post-automation services,Contract manufacturing and integration services,
BIOTEST AG	Germany	Public Company	Immunoglobulins (Intratect, Yimmugo, Pentaglobin, Cytotect, Varitect, Hepatect, Fovepta),Coagulation factors and hemostasis (Haemoctin, Haemonine, Cofact, Fibrinogen),Albumin and volume replacement (Albiomin, Biseko),
GREEN CROSS	Australia	Private Company	Retail (pet food, products, accessories, in-store services),Veterinary (general practice, emergency, specialty, pathology, crematoria),
TAKEDA PHARMACEUTICAL COMPANY	Japan	Public Company	Gastroenterology (Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA),Rare Diseases & Plasma-Derived Therapies (Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin),Oncology (Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig),
ZYDUS CADILA	India	Public Company	Pharmaceuticals (APIs, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics),Consumer Products (consumer wellness, seasonal, skin and healthcare, food and nutrition),Medical Technologies and Animal Health,
FLUOR CORPORATION	United States	Public Company	Energy Solutions,Urban Solutions,Mission Solutions,
MAXCYTE, INC	United States	Public Company	ExPERT GTx and VLx (therapeutic-scale electroporation),ExPERT STx (flow electroporation for protein and drug discovery),ExPERT ATx (static electroporation, small–medium scale),
HELM AG	Germany	Private Company	Fertilizers and crop protection,Industrial chemicals (organic/inorganic, acids, lyes),Plastics and polyurethane chemicals,
MODERNA INC	United States	Public Company	COVID/Spikevax and pandemic influenza vaccines,Respiratory vaccines (RSV, seasonal influenza, combinations),Oncology therapeutics (intismeran autogene, cancer antigen, T-cell engagers),
BIONTECH SE	Germany	Public Company	BNT162 COVID-19 vaccine,Oncology pipeline (late-stage: Gotistobart, Pumitamig, Trastuzumab pamirtecan, BNT113),Oncology pipeline (mid/early-stage: BNT116, BNT326/YL202, Autogene cevumeran, others),
CANSINO BIOLOGICS INC	China	Public Company	COVID-19 vaccines (including Ad5-nCoV for inhalation),Meningococcal vaccines (MCV2, MCV4, CS-2023 pipeline),Pediatric pertussis-containing vaccines (DTcP, DTcP Booster, Tdcp adolescent/adult, DTcP-Hib combo),
SAMSUNG BIOLOGICS	South Korea	Public Company	Drug substance manufacturing (mAbs and biologics),Fill-finish, lyophilization, and cold-chain services,Development and analytical services,
AZELIS HOLDINGS SA	Belgium	Private Company	Food and Nutrition Ingredients,Personal Care and Home Care Ingredients,Pharma and Life Sciences,
GSK PLC	United Kingdom	Public Company	Vaccines,Specialty Medicines,General Medicines,
MERCK & CO., INC.	United States	Public Company	Human pharmaceuticals – oncology and specialty,Human pharmaceuticals – vaccines,Human pharmaceuticals – infectious disease, cardiometabolic, and other,
PFIZER INC.	India	Public Company	Internal medicine (cardiovascular, respiratory, gastroenterology, pain, multivitamins, nutrition),Anti-infectives and injectables (hospital-focused),Vaccines,
SANOFI	France	Public Company	Vaccines (pediatric, RSV, hexavalent, travel and endemic vaccines),Immunology and inflammation therapies,Rare diseases and neurology,
CSL	Australia	Public Company	Licensing & other IP-related income,
EMERGENT	United States	Public Company	Anthrax vaccines and therapeutics (BioThrax, CYFENDUS, ANTHRASIL, Raxibacumab),Smallpox/mpox vaccines and antivirals (ACAM2000, TEMBEXA, CNJ-016),Opioid overdose reversal (NARCAN, KLOXXADO),
ASTRAZENECA	United Kingdom	Public Company	Oncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Imjudo, Orpathys, Truqap, Faslodex, Zoladex, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, Onglyza, XIGDUO, Komboglyze, Qtern, others),Respiratory & Immunology (Symbicort, Pulmicort, Fasenra, Tezspire, Breztri, Airsupra, Saphnelo, others),
BAVARIAN NORDIC	Denmark	Public Company	Non-replicating smallpox and monkeypox vaccines (IMVAMUNE/IMVANEX/JYNNEOS),Rabies vaccine (Rabipur/RabAvert),Tick-borne encephalitis vaccine (Encepur),
MITSUBISHI TANABE PHARMA CORPORATION	Japan	Private Company	Prescription pharmaceuticals – CNS, immuno-inflammation, diabetes, kidney disorders,Vaccines (influenza and pediatric/combined indications),OTC products (skin-treating agents, digestive drinks and medicines, nutrient foods),
DAIICHI SANKYO COMPANY, LIMITED	Japan	Public Company	Oncology (Enhertu, Turalio, Vanflyta, Datroway, NSCLC and solid tumor portfolio),Cardiovascular and metabolic (Lixiana/Savaysa, antihypertensives, Nilemdo, Nustendi, Efient, Canalia),Neurology, pain, bone health, and iron therapies (Emgality, Reyvow, Tarlige, Pralia, Ranmark, Vimpat, Injectafer, Venofer),
PANACEA BIOTEC	India	Public Company	Vaccines,Pharmaceutical Formulations,Nutrition, Nutraceuticals, and Other (including Real Estate),

ATS AUTOMATION TOOLING SYSTEMS INC

ATS Automation Tooling Systems Inc is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.

BIOTEST AG

Biotest AG is a German public company founded in 1946 with 2,698 employees. The company operates in the pharmaceutical and biotechnology sectors.

GREEN CROSS

Green Cross is an Australian private company founded in 1994 with 5,109 employees. The company operates in the healthcare and pharmaceutical industries.

TAKEDA PHARMACEUTICAL COMPANY

Takeda Pharmaceutical Company is a Japanese public company founded in 1781 with 47,029 employees. The company is a major global pharmaceutical manufacturer and developer.

ZYDUS CADILA

Zydus Cadila is an Indian public company founded in 1952 with 29,980 employees. The company is a leading pharmaceutical and biotechnology manufacturer.

FLUOR CORPORATION

Fluor Corporation is a United States-based public company founded in 1912 with 22,995 employees. The company provides engineering, procurement, and construction services across multiple industries.

MAXCYTE, INC

MaxCyte, Inc. is a United States-based public company founded in 1998 with 91 employees. The company develops cell engineering technologies and solutions.

HELM AG

Helm AG is a German private company founded in 1900 with 1,430 employees. The company operates in the chemical and pharmaceutical distribution sectors.

MODERNA INC

Moderna Inc is a United States-based public company founded in 2010 with 4,700 employees. The company specializes in messenger RNA (mRNA) technology and vaccine development.

BIONTECH SE

BioNTech SE is a German public company founded in 2008 with 7,807 employees. The company develops immunotherapies and vaccines using biotechnology platforms.

CANSINO BIOLOGICS INC

CanSino Biologics Inc is a Chinese public company founded in 2009 with 1,134 employees. The company develops and manufactures vaccines and biopharmaceuticals.

SAMSUNG BIOLOGICS

Samsung Biologics is a South Korean public company founded in 2011 with 5,195 employees. The company provides contract manufacturing and biopharmaceutical production services.

AZELIS HOLDINGS SA

Azelis Holdings SA is a Belgian private company founded in 2001 with 1,325 employees. The company specializes in specialty chemicals and ingredients.

GSK PLC

GSK PLC is a United Kingdom-based public company founded in 1715 with 66,841 employees. The company is a major global pharmaceutical, vaccine, and consumer healthcare manufacturer.

MERCK & CO., INC.

Merck & Co., Inc. is a United States-based public company founded in 1891 with 74,000 employees. The company is a leading global pharmaceutical and healthcare products manufacturer.

PFIZER INC.

Pfizer Inc. is an India-based public company founded in 1950 with 1,244 employees. The company manufactures and distributes pharmaceutical products.

SANOFI

Sanofi is a French public company founded in 1994 with 74,846 employees. The company is a major global pharmaceutical manufacturer specializing in vaccines, drugs, and consumer healthcare.

CSL

CSL is an Australian public company founded in 1916 with 29,904 employees. The company is a leading global biopharmaceutical manufacturer specializing in plasma-derived therapies and vaccines.

EMERGENT

Emergent is a United States-based public company founded in 1998 with 900 employees. The company provides contract manufacturing and development services for vaccines and biopharmaceuticals.

ASTRAZENECA

AstraZeneca is a United Kingdom-based public company founded in 1992 with 96,100 employees. The company is a major global pharmaceutical manufacturer specializing in oncology, cardiovascular, and respiratory medicines.

BAVARIAN NORDIC

Bavarian Nordic is a Danish public company founded in 1992 with 1,861 employees. The company develops and manufactures vaccines for infectious diseases.

MITSUBISHI TANABE PHARMA CORPORATION

Mitsubishi Tanabe Pharma Corporation is a Japanese private company founded in 2007 with 6,756 employees. The company develops and manufactures pharmaceutical products.

DAIICHI SANKYO COMPANY, LIMITED

Daiichi Sankyo Company, Limited is a Japanese public company founded in 1899 with 20,171 employees. The company is a global pharmaceutical manufacturer specializing in innovative medicines.

PANACEA BIOTEC

Panacea Biotec is an Indian public company founded in 1984 with 2,149 employees. The company develops and manufactures vaccines and biopharmaceuticals.

Reasons to Buy this Report

Regional Market Sizing & Forecasts : Obtain precise market valuations specific to Rest Of Asia Pacific (USD 187.8M in 2025, USD 290.3M in 2030) with detailed CAGR analysis to support strategic planning and investment decisions.
Competitive Landscape Intelligence : Understand key players, market share distribution, and competitive dynamics unique to Rest Of Asia Pacific to identify partnership opportunities and market entry strategies.
Growth Driver Analysis : Gain insights into region-specific growth catalysts including government initiatives, healthcare infrastructure expansion, and immunization awareness trends driving vaccine adoption in Rest Of Asia Pacific.
Emerging Economy Opportunities : Identify high-potential emerging markets within Rest Of Asia Pacific with detailed country-level analysis, regulatory environments, and market penetration opportunities for vaccine manufacturers.
Strategic Market Positioning : Develop targeted go-to-market strategies for Rest Of Asia Pacific by understanding regional healthcare spending patterns, vaccination coverage gaps, and distribution channel preferences.

Frequently asked questions

What is the current market size of vaccines in Rest Of Asia Pacific?

Rest Of Asia Pacific vaccines market is valued at USD 187.8 million in 2025 and is projected to grow to USD 290.3 million by 2030.

What is the growth rate for vaccines in Rest Of Asia Pacific?

Rest Of Asia Pacific vaccines market is growing at a compound annual growth rate (CAGR) of 9.1% from 2025 to 2030, outpacing the global average of 7.3%.

What factors are driving growth in Rest Of Asia Pacific vaccines market?

Rest Of Asia Pacific growth is driven by increasing immunization awareness, expanding healthcare infrastructure, government vaccination initiatives, improved cold chain logistics, and rising disposable incomes across emerging economies.

How does Rest Of Asia Pacific compare to the global vaccines market?

Rest Of Asia Pacific grows at 9.1% CAGR, significantly faster than the global rate of 7.3%, reflecting strong demand in emerging markets and expanding healthcare access across the region.

What opportunities exist for vaccine manufacturers in Rest Of Asia Pacific?

Rest Of Asia Pacific presents significant opportunities through government immunization programs, expanding middle-class populations, improving distribution networks, and rising preventive healthcare adoption in underserved areas.

RESEARCH METHODOLOGY

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global vaccines market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the vaccines market. The secondary sources used for this study include World Health Organization (WHO), the Organisation for Economic Co-operation and Development (OECD), National Center for Biotechnology Information (NCBI), Centers for Disease Control and Prevention (CDC), the Global Cancer Observatory (GLOBOCAN), the National Institutes of Health (NIH), Center of Disease Control & Prevention (CDC), US Department of Health and Human Services, National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information (NCBI), National Institute of Allergy and Infectious Diseases (NIAID), World Cancer Research Fund International (WCRF International), European Medicines Agency (EMA), The National Medical Products Administration (NMPA), Global Alliance for Vaccines and Immunization (GAVI), United States Food & Drug Administration (US FDA), Orange book, Purple book, Clinical trials.gov, Pan American Health Organization (PAHO), United Nation International Children’s Emergency Fund (UNICEF), Department of health and Human Services (HHS), and International Society for Vaccines (ISV). Corporate filings include annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to determine the overall size of the global vaccines market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and assess future market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Vaccines Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were employed to estimate and validate the overall size of the vaccines market. These methods were also widely used to determine the size of various market segments. The research methodology used to estimate the market size includes the following:

Vaccines Market: Top-Down and Bottom-Up Approach

Data Triangulation

After estimating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown techniques were used where applicable to finalize the overall market analysis and obtain precise statistics for all segments and subsegments. The data was triangulated by examining various factors and trends from both demand and supply sides.

Market Definition

A vaccine is a biologically formulated product designed to trigger active acquired immunity against a specific infectious or malignant disease. Vaccines work by stimulating the immune system to identify and fight harmful agents, such as viruses or bacteria. They generally consist of parts that resemble the disease-causing microorganism, often in weakened or deactivated forms, along with their toxins or surface proteins.
The vaccines market comprises commercially available biological preparations administered to humans to stimulate active immunity against specific infectious diseases. The report solely focuses on human vaccines and does not include veterinary vaccines, which are outside the scope of this study. The scope of this report includes conjugate vaccines, inactivated & subunit vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, and other vaccines.

Key Stakeholders

Vaccine product manufacturers and suppliers
Distributors and suppliers of vaccine products
Vaccine research institutes
Biotechnology and biopharmaceutical companies
Contract manufacturing organizations (CMOs)
Contract development and manufacturing organizations (CDMO)
Suppliers and distributors of pharmaceutical products
Research and development (R&D) companies
Drug Manufacturers, Vendors, and Distributors
Immunization centres
Hospitals and laboratories
Trade associations and industry bodies
Regulatory bodies and government organizations
Venture capitalists and investors
Hospitals
Specialty Clinics

Report Objectives

To define, describe, and forecast the vaccines market by technology, type, disease indication, route of administration, end user, and region
To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall vaccines market
To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
To profile the key players and analyze their market shares and core competencies
To track and analyze competitive developments, such as product launches, agreements, partnerships, acquisitions, regulatory approvals, and research & development activities
To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the vaccines market

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet the company’s specific needs. The following customization options are available for this report:

Portfolio Assesment

Product Matrix gives a detailed comparison of the product portfolios of the top five companies.

Geographic Analysis

Further breakdown of the Rest of Europe vaccines market, by country
Further breakdown of the Rest of Asia Pacific vaccines market, by country
Further breakdown of the Rest of Latin America vaccines market, by country

Get the Full Vaccines Market Report

Full forecast, segment splits, and company analysis for all Vaccines Market.

Download Sample Pages Buy Report

REPORT COVERAGE

＋

Report Description
Market Overview
Market Dynamics
Related Ecosystem
Key Takeaways
Market Scope
Report Segmentation
Target Audience
Key Companies

Market Size in	USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered	Value (USD MN)

COMPANY	USE CASE DESCRIPTION	BENEFITS
	Moderna’s new center at the Harwell science campus, which is home to over 250 organizations in health, technology, and energy, will manufacture mRNA vaccines for the NHS’s seasonal immunization programs \| The facility already has a license to produce COVID-19 vaccines and is preparing to apply for regulatory approval to manufacture flu vaccines as well.	Strengthens domestic mRNA vaccine manufacturing capacity, enhancing the UK’s preparedness against emerging infectious diseases and seasonal threats \| Accelerates the availability of advanced vaccines within the NHS, reducing reliance on international supply chains \| The new facility also encourages further innovation in mRNA vaccine technology and supports rapid scale-up during future public health emergencies.
	After a series of vaccine expansion projects, Sanofi is pursuing a new strategy to extend the reach of its immunizations in Vietnam \| Partnering with the Vietnam Vaccine Company (VNVC), Sanofi has initiated a technology transfer for vaccine production, aiming to eventually manufacture select Sanofi vaccines locally within Vietnam.	Crucial as it expands local manufacturing capabilities, reducing dependence on imports and strengthening supply chain resilience in Southeast Asia \| Access and affordability could significantly improve, helping to address public health needs more efficiently.